BioSpace News Archive

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, today announced the company’s Scientific Advisory Board (SAB).

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA clearance of its TJF-Q190V duodenoscope with a sterile, disposable distal endcap.

McGinley Orthopedics, a developer of innovative HandHeld Robotic technology with a goal of changing the standard of medical care, has a new product

Elekta (EKTA-B.ST) today announced that its Versa HD™ linear accelerator and MOSAIQ® Oncology Information System (OIS) have been selected as Category Leaders in the 2020 Best in KLAS: Software and Services Report.

Waystar, a leading provider of revenue cycle technology, received top honors in the 2020 Best in KLAS Software and Services report for the Claims and Clearinghouse segment

Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its shares have received Depository Trust Company (“DTC”) full-service eligibility in the United States.

Two innovative technologies from Dow (NYSE:DOW), the world’s leading materials science company, were recognized with 2020 BIG Innovation Awards presented by the Business Intelligence Group.

McKesson High Volume Solutions (HVS) and Coborn’s are pleased to announce the integration of ExpressRx Track with Coborn’s pharmacy operations.

RealSelf, the go-to destination for making cosmetic treatment decisions and connecting with doctors, today announced the 2020 Most Worth It Ranking—a comprehensive list of the top-rated cosmetic procedures

Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more than $200,000 in funding, with the potential for multiple years, to support a Phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist (DRD2), in a molecular subset of high grade gliomas.